Novartis stock has delivered a 92.5% return over the past 5 years, which raises a clear valuation question for investors now that market multiples still screen it as undervalued while broader checks point to a more mixed picture. Over 5 years, Novartis has returned 92.5%, which places recent share performance firmly in focus when judging whether current pricing already reflects much of the progress. Upcoming cardiovascular data at the 2026 ESC Congress and the recent UK court win protecting...

Novartis (SWX:NOVN) is drawing fresh attention after announcing plans to present data from 10 cardiovascular abstracts at the 2026 European Society of Cardiology Congress, spanning LDL cholesterol, atrial fibrillation and heart failure. See our latest analysis for Novartis. Alongside the upcoming ESC data, Novartis has seen firm price momentum, with a 1-month share price return of 3.27% and a year to date share price return of 17.16%. The 5-year total shareholder return of 92.48% points to...

Novartis (SWX:NOVN) plans to present late breaking data from multiple pivotal cardiovascular studies at the 2026 European Society of Cardiology Congress. The presentations include head to head Phase IV results for Leqvio in LDL C management. New analyses on bleeding risk for abelacimab in atrial fibrillation are also scheduled for the ESC 2026 program. These data may influence future treatment guidelines and physician use of Novartis cardiovascular therapies. Investors watching how large...

Palantir Stock Rises as Fresh AI Demand Keeps Post-Earnings Momentum Alive

A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.

The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand.

(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.) Novartis

Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.

BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?

Higher Darzalex and Kesimpta royalties supported a $195 million increase in Genmab's annual revenue-guidance midpoint.

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.